|
|
Aequus Announces Marc Lustig Joining Board of Directors and Making Direct Equity Investment into the Company
|
Vancouver, BC, February 17, 2021--Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF), a specialty pharmaceutical company with a focus on developing, advancing and promoting differentiated products announced that it intends to complete a non-brokered private placement of 6,666,666 units of the Company at a price of $0.15 per Unit, for aggregate gross proceeds of $1,000,000 to Marc Lustig, who has concurrently agreed to join the Aequus Board of Directors as described below.
|
|
|
|
|
Aequus Provides Third Quarter 2020 Financial Highlights
|
Vancouver, BC, December 15, 2020--Aequus Pharmaceuticals Inc. (TSX-V: AQS), a specialty pharmaceutical company with a focus on developing, advancing and promoting differentiated products, reported financial results for the three months ended September 30, 2020 and associated Company developments.
|
|
|
|
|
Aequus Announces Leadership Change, Anne Stevens Stepping Down as Chief Operating Officer
|
Vancouver, BC, December 9, 2020--Aequus Pharmaceuticals Inc. (TSX-V: AQS), a specialty pharmaceutical company with a focus on developing, advancing and promoting differentiated products announced that Ms Anne Stevens is stepping down from her role as Chief Operating Officer. Ms Stevens will remain a Director and will continue to serve on the Aequus Board of Directors.
|
|
|
|
|
|
|
|
Aequus Provides General Update and Second Quarter 2020 Financial Highlights
|
Vancouver, BC, September 9, 2020--Aequus Pharmaceuticals Inc. (TSX-V: AQS), a specialty pharmaceutical company with a focus on developing, advancing and promoting differentiated products, reported financial results for the three months ended June 30, 2020 and six months ended June 30, 2020 and associated Company developments.
|
|
|
|
|
Aequus Announces New Chief Commercial Officer
|
Vancouver, BC, August 26, 2020--Aequus Pharmaceuticals Inc. (TSX-V: AQS), a specialty pharmaceutical company with a focus on developing, advancing and promoting differentiated products, announced that Grant Larsen has been appointed to the Aequus Team as Chief Commercial Officer.
|
|
|
|
|
Aequus Announces Positive Update on Dry Eye Product Launch Plans
|
Vancouver, BC, April 30, 2020--Aequus Pharmaceuticals Inc. (TSX-V: AQS), a specialty pharmaceutical company with a focus on developing, advancing and promoting differentiated products, announced this week a positive update on the regulatory and launch advancement for its Evolve® line of preservative free dry eye products into Canada.
|
|
|
|
|
Aequus Announces Positive Update on Dry Eye Product Launch Plans
|
Vancouver, BC, April 22, 2020--Aequus Pharmaceuticals Inc. (TSX-V: AQS), a specialty pharmaceutical company with a focus on developing, advancing and promoting differentiated products, announced a positive update on the regulatory and launch advancement for the Evolve® line of preservative free dry eye products into Canada.
|
|
|
|